Clinical Trial

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of Human Derived anti-BCMA CAR-T Injection , and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory multiple myeloma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-03-27.
Status change: Recruiting → Active, Not Recruiting 2025-01-01
Trial Details
NCT Number NCT05302648
Lead Sponsor Hrain Biotechnology Co., Ltd.
Collaborators: Shanghai Changzheng Hospital
Conditions Multiple Myeloma
Enrollment 18 participants
Start Date 2022-02-09
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-03